Prevalence of Chlamydia trachomatis Infection in Young Women and Associated Predictors.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
11
6
2021
medline:
3
8
2021
entrez:
10
6
2021
Statut:
ppublish
Résumé
Chlamydia trachomatis (CT) infection remains highly prevalent, and young women are disproportionately affected. Most CT-infected women are asymptomatic, and their infection often goes unrecognized and untreated. We hypothesized that testing for active CT infection with molecular diagnostics and obtaining a reported history of CT infection underestimate the prevalence of current and past CT infection, and incorporating serum CT antibody testing in addition to these other prevalence measures would generate more accurate estimates of the prevalence of CT infection in asymptomatic young women. We enrolled 362 asymptomatic women aged 16 to 29 years at 4 different clinical settings in Birmingham, AL, between August 2016 and January 2020 and determined the prevalence of CT infection based on having 1 or more of the following prevalence measures: an active urogenital CT infection based on molecular testing, reported prior CT infection, and/or being CT seropositive. Multivariable regression analysis was used to determine predictors of the prevalence of CT infection after adjustment for participant characteristics. The prevalence of CT infection was 67.7% (95% confidence interval, 62.6%-72.5%). Addition of CT antibody testing to the other individual prevalence measures more than doubled the CT infection prevalence. Non-Hispanic Black race, reported prior gonorrhea, and reported prior trichomoniasis predicted a higher prevalence of CT infection. More than half of women were unaware of ever having CT infection, suggesting many were at risk for CT-associated reproductive complications. These data reinforce the need to adhere to chlamydia screening guidelines and to increase screening coverage in those at risk.
Sections du résumé
BACKGROUND
Chlamydia trachomatis (CT) infection remains highly prevalent, and young women are disproportionately affected. Most CT-infected women are asymptomatic, and their infection often goes unrecognized and untreated. We hypothesized that testing for active CT infection with molecular diagnostics and obtaining a reported history of CT infection underestimate the prevalence of current and past CT infection, and incorporating serum CT antibody testing in addition to these other prevalence measures would generate more accurate estimates of the prevalence of CT infection in asymptomatic young women.
METHODS
We enrolled 362 asymptomatic women aged 16 to 29 years at 4 different clinical settings in Birmingham, AL, between August 2016 and January 2020 and determined the prevalence of CT infection based on having 1 or more of the following prevalence measures: an active urogenital CT infection based on molecular testing, reported prior CT infection, and/or being CT seropositive. Multivariable regression analysis was used to determine predictors of the prevalence of CT infection after adjustment for participant characteristics.
RESULTS
The prevalence of CT infection was 67.7% (95% confidence interval, 62.6%-72.5%). Addition of CT antibody testing to the other individual prevalence measures more than doubled the CT infection prevalence. Non-Hispanic Black race, reported prior gonorrhea, and reported prior trichomoniasis predicted a higher prevalence of CT infection.
CONCLUSIONS
More than half of women were unaware of ever having CT infection, suggesting many were at risk for CT-associated reproductive complications. These data reinforce the need to adhere to chlamydia screening guidelines and to increase screening coverage in those at risk.
Identifiants
pubmed: 34110759
pii: 00007435-202108000-00003
doi: 10.1097/OLQ.0000000000001372
pmc: PMC8847232
mid: NIHMS1776373
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-535Subventions
Organisme : NIAID NIH HHS
ID : K24 AI125685
Pays : United States
Informations de copyright
Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest and Sources of Funding: W.M.G. and B.V.D.P. report receiving research funding from Hologic, Inc, outside the range of the current work. The other authors report no potential conflicts of interest.
Références
Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 2015; 10:e0143304.
Sexually Transmitted Diseases Surveillance 2018. Atlanta, GA: Centers for Disease Control and Prevention, 2019.
Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40:187–193.
O'Connell CM, Ferone ME. Chlamydia trachomatis genital infections. Microb Cell 2016; 3:390–403.
Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with chlamydia and gonorrhea among females: A systematic review of the literature. Sex Transm Dis 2009; 36:478–489.
Xu F, Stoner BP, Taylor SN, et al. Use of home-obtained vaginal swabs to facilitate rescreening for Chlamydia trachomatis infections: Two randomized controlled trials. Obstet Gynecol 2011; 118:231–239.
Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1–137.
Hoover KW, Leichliter JS, Torrone EA, et al. Chlamydia screening among females aged 15–21 years—Multiple data sources, United States, 1999–2010. MMWR Suppl 2014; 63:80–88.
Geisler WM, Chyu L, Kusunoki Y, et al. Health insurance coverage, health care–seeking behaviors, and genital chlamydial infection prevalence in sexually active young adults. Sex Transm Dis 2006; 33:389–396.
Hoover KW, Tao G, Nye MB, et al. Suboptimal adherence to repeat testing recommendations for men and women with positive chlamydia tests in the United States, 2008–2010. Clin Infect Dis 2013; 56:51–57.
Molano M, Meijer CJ, Weiderpass E, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: A 5-year follow-up study. J Infect Dis 2005; 191:907–916.
Morre SA, van den Brule AJ, Rozendaal L, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% Clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002; 13(Suppl 2):12–18.
Geisler WM. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: A review of human studies. J Infect Dis 2010; 201(Suppl 2):S104–S113.
Geisler WM, Morrison SG, Doemland ML, et al. Immunoglobulin-specific responses to chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. J Infect Dis 2012; 206:1836–1843.
Gupta K, Brown L, Bakshi RK, et al. Performance of Chlamydia trachomatis OmcB enzyme-linked immunosorbent assay in serodiagnosis of Chlamydia trachomatis infection in women. J Clin Microbiol 2018; 56:e00275–e00218.
Bakshi R, Gupta K, Jordan SJ, et al. Immunoglobulin-based investigation of spontaneous resolution of Chlamydia trachomatis infection. J Infect Dis 2017; 215:1653–1656.
Woodhall SC, Wills GS, Horner PJ, et al. Chlamydia trachomatis Pgp3 antibody population seroprevalence before and during an era of widespread opportunistic chlamydia screening in England (1994–2012). PLoS One 2017; 12:e0152810.
Horner PJ, Wills GS, Righarts AV, et al. Chlamydia trachomatis Pgp3 antibody persists and correlates with self-reported infection and behavioural risks in a blinded cohort study. PLoS One 2016; 11:e0151497.
Dize L, Martin D, Gwyn S, et al. Comparison of three serological assays to measure antibody response to chlamydia antigen Pgp3 in adolescent and young adults with pelvic inflammatory disease. Int J STD AIDS 2018; 29:1324–1329.
National Committee for Quality Assurance. State of Health Care Quality Report. Available at: https://www.ncqa.org/hedis/measures/chlamydia-screening-in-women/ . Accessed May 9, 2020.
Learner ER, Torrone EA, Fine JP, et al. Chlamydia prevalence trends among women and men entering the National Job Training Program from 1990 through 2012. Sex Transm Dis 2018; 45:554–559.
Nguyen TQ, Ford CA, Kaufman JS, et al. Infrequent chlamydial testing among young adults: Financial and regional differences. Sex Transm Dis 2008; 35:725–730.
Datta SD, Torrone E, Kruszon-Moran D, et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999–2008. Sex Transm Dis 2012; 39:92–96.
Sales JM, Smearman EL, Swartzendruber A, et al. Socioeconomic-related risk and sexually transmitted infection among African-American adolescent females. J Adolesc Health 2014; 55:698–704.
Hamilton DT, Morris M. The racial disparities in STI in the U.S.: Concurrency, STI prevalence, and heterogeneity in partner selection. Epidemics 2015; 11:56–61.
Gorwitz RJ, Wiesenfeld HC, Chen PL, et al. Population-attributable fraction of tubal factor infertility associated with chlamydia. Am J Obstet Gynecol 2017; 217:336.e1–336.e16.